FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308711092> ?p ?o ?g. }

• W4308711092 endingPage "e002995" @default.
• W4308711092 startingPage "e002995" @default.
• W4308711092 abstract "Introduction Several new oral drug classes for type 2 diabetes (T2DM) have been introduced in the last 20 years accompanied by developments in clinical evidence and guidelines. The uptake of new therapies and contemporary use of blood glucose-lowering drugs has not been closely examined in Canada. The objective of this project was to describe these treatment patterns and relate them to changes in provincial practice guidelines. Research design and methods We conducted a longitudinal drug utilization study among persons with T2DM aged ≥18 years from 2001 to 2020 in British Columbia (BC), Canada. We used dispensing data from community pharmacies with linkable physician billing and hospital admission records. Laboratory results were available from 2011 onwards. We identified incident users of blood glucose-lowering drugs, then determined sequence patterns of medications dispensed, with stratification by age group, and subgroup analysis for patients with a history of cardiovascular disease. Results Among a cohort of 362 391 patients (mean age 57.7 years old, 53.5% male) treated for non-insulin-dependent diabetes, the proportion who received metformin monotherapy as first-line treatment reached a maximum of 90% in 2009, decreasing to 73% in 2020. The proportion of patients starting two-drug combinations nearly doubled from 3.3% to 6.4%. Sulfonylureas were the preferred class of second-line agents over the course of the study period. In 2020, sodium-glucose cotransporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists accounted for 21% and 10% of second-line prescribing, respectively. For patients with baseline glycated hemoglobin (A1C) results prior to initiating diabetic treatment, 41% had a value ≤7.0% and 27% had a value over 8.5%. Conclusions Oral diabetic medication patterns have changed significantly over the last 20 years in BC, primarily in terms of medications used as second-line therapy. Over 40% of patients with available laboratory results initiated T2DM treatment with an A1C value ≤7.0%, with the average A1C value trending lower over the last decade." @default.
• W4308711092 created "2022-11-14" @default.
• W4308711092 creator A5040817296 @default.
• W4308711092 creator A5065006086 @default.
• W4308711092 creator A5065904248 @default.
• W4308711092 creator A5072130564 @default.
• W4308711092 creator A5073931268 @default.
• W4308711092 creator A5085093112 @default.
• W4308711092 creator A5091747508 @default.
• W4308711092 date "2022-11-01" @default.
• W4308711092 modified "2023-10-15" @default.
• W4308711092 title "Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada" @default.
• W4308711092 cites W1489703055 @default.
• W4308711092 cites W2095784604 @default.
• W4308711092 cites W2146264128 @default.
• W4308711092 cites W2149769792 @default.
• W4308711092 cites W2163278718 @default.
• W4308711092 cites W2406779066 @default.
• W4308711092 cites W2418321945 @default.
• W4308711092 cites W2425644022 @default.
• W4308711092 cites W2461457548 @default.
• W4308711092 cites W2519510391 @default.
• W4308711092 cites W2558369602 @default.
• W4308711092 cites W2626446274 @default.
• W4308711092 cites W2742200852 @default.
• W4308711092 cites W2753603256 @default.
• W4308711092 cites W2765545378 @default.
• W4308711092 cites W2802245520 @default.
• W4308711092 cites W2883091608 @default.
• W4308711092 cites W2900413769 @default.
• W4308711092 cites W2971135507 @default.
• W4308711092 cites W2983229458 @default.
• W4308711092 cites W2987589037 @default.
• W4308711092 cites W3032350368 @default.
• W4308711092 cites W3036051596 @default.
• W4308711092 cites W3088173406 @default.
• W4308711092 cites W3089099811 @default.
• W4308711092 cites W3100542962 @default.
• W4308711092 cites W3111093755 @default.
• W4308711092 cites W3112336702 @default.
• W4308711092 cites W4210633796 @default.
• W4308711092 cites W4211058450 @default.
• W4308711092 cites W4220706492 @default.
• W4308711092 cites W4225964173 @default.
• W4308711092 cites W4252551839 @default.
• W4308711092 doi "https://doi.org/10.1136/bmjdrc-2022-002995" @default.
• W4308711092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36356988" @default.
• W4308711092 hasPublicationYear "2022" @default.
• W4308711092 type Work @default.
• W4308711092 citedByCount "5" @default.
• W4308711092 countsByYear W43087110922023 @default.
• W4308711092 crossrefType "journal-article" @default.
• W4308711092 hasAuthorship W4308711092A5040817296 @default.
• W4308711092 hasAuthorship W4308711092A5065006086 @default.
• W4308711092 hasAuthorship W4308711092A5065904248 @default.
• W4308711092 hasAuthorship W4308711092A5072130564 @default.
• W4308711092 hasAuthorship W4308711092A5073931268 @default.
• W4308711092 hasAuthorship W4308711092A5085093112 @default.
• W4308711092 hasAuthorship W4308711092A5091747508 @default.
• W4308711092 hasBestOaLocation W43087110921 @default.
• W4308711092 hasConcept C104863432 @default.
• W4308711092 hasConcept C126322002 @default.
• W4308711092 hasConcept C134018914 @default.
• W4308711092 hasConcept C2777180221 @default.
• W4308711092 hasConcept C2777538456 @default.
• W4308711092 hasConcept C2778176773 @default.
• W4308711092 hasConcept C2779306644 @default.
• W4308711092 hasConcept C2780035454 @default.
• W4308711092 hasConcept C2780323712 @default.
• W4308711092 hasConcept C512399662 @default.
• W4308711092 hasConcept C555293320 @default.
• W4308711092 hasConcept C71924100 @default.
• W4308711092 hasConcept C72563966 @default.
• W4308711092 hasConcept C98274493 @default.
• W4308711092 hasConceptScore W4308711092C104863432 @default.
• W4308711092 hasConceptScore W4308711092C126322002 @default.
• W4308711092 hasConceptScore W4308711092C134018914 @default.
• W4308711092 hasConceptScore W4308711092C2777180221 @default.
• W4308711092 hasConceptScore W4308711092C2777538456 @default.
• W4308711092 hasConceptScore W4308711092C2778176773 @default.
• W4308711092 hasConceptScore W4308711092C2779306644 @default.
• W4308711092 hasConceptScore W4308711092C2780035454 @default.
• W4308711092 hasConceptScore W4308711092C2780323712 @default.
• W4308711092 hasConceptScore W4308711092C512399662 @default.
• W4308711092 hasConceptScore W4308711092C555293320 @default.
• W4308711092 hasConceptScore W4308711092C71924100 @default.
• W4308711092 hasConceptScore W4308711092C72563966 @default.
• W4308711092 hasConceptScore W4308711092C98274493 @default.
• W4308711092 hasFunder F4320322836 @default.
• W4308711092 hasIssue "6" @default.
• W4308711092 hasLocation W43087110921 @default.
• W4308711092 hasLocation W43087110922 @default.
• W4308711092 hasLocation W43087110923 @default.
• W4308711092 hasLocation W43087110924 @default.
• W4308711092 hasLocation W43087110925 @default.
• W4308711092 hasOpenAccess W4308711092 @default.
• W4308711092 hasPrimaryLocation W43087110921 @default.
• W4308711092 hasRelatedWork W2017470589 @default.

• next